KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Amortization (2016 - 2026)

Gsk has reported Amortization over the past 18 years, most recently at $4.3 billion for Q1 2026.

  • For Q1 2026, Amortization fell 19.45% year-over-year to $4.3 billion; the TTM value through Mar 2026 reached $17.8 billion, up 63.42%, while the annual FY2025 figure was $22.3 billion, 11.87% up from the prior year.
  • Amortization for Q1 2026 was $4.3 billion at Gsk, down from $8.4 billion in the prior quarter.
  • Over five years, Amortization peaked at $19.4 billion in Q3 2023 and troughed at $84.5 million in Q3 2024.
  • A 5-year average of $5.6 billion and a median of $2.9 billion in 2022 define the central range for Amortization.
  • Biggest five-year swings in Amortization: tumbled 99.56% in 2024 and later soared 3325.55% in 2025.
  • Year by year, Amortization stood at $18.3 billion in 2022, then plummeted by 64.04% to $6.6 billion in 2023, then plummeted by 42.51% to $3.8 billion in 2024, then soared by 120.86% to $8.4 billion in 2025, then crashed by 48.44% to $4.3 billion in 2026.
  • Business Quant data shows Amortization for GSK at $4.3 billion in Q1 2026, $8.4 billion in Q4 2025, and $2.9 billion in Q3 2025.